Article Sidebar
Published:
Mar 12, 2024DOI:
10.4314/tjpr.v23i2.9Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of cinnamaldehyde on nesfatin-1 levels in diabetic rats
Abstract
Purpose: To evaluate the effect of cinnamaldehyde (CA) on fasting blood glucose (FBG), body weight, lipid profile, and nesfatin-1 levels in healthy and diabetic (DM) rats.
Methods: Ten groups with eight rats per group were used. Healthy and diabetic sham groups were administered 1 mL of saline for 28 days by intragastric gavage. Healthy and diabetic control groups were administered 1 mL 0.5 % dimethyl sulfoxide (DMSO) for 28 days by intragastric gavage. Other diabetic and healthy groups (HG) received 10, 20, and 40 mg/kg CA for 28 days by intragastric gavage, once daily. Diabetes was induced with streptozotocin (50 mg/kg intraperitoneally). Rats were defined as diabetic when FBG was > 250 mg/dL. Enzyme-linked immunosorbent assay (ELISA) was used to assess serum nesfatin-1 concentrations. Fasting blood glucose (FBG) values were evaluated with a glucometer.
Results: Day 28 weights of all DM and HG + 40 mg/kg CA groups were lower than day 1 weights (p < 0.05). Triglyceride values of DM + 40 mg/kg CA group were lower than DM sham and control group (p ≤ 0.001). Low-density lipoprotein (LDL) and cholesterol levels of the CA-administered healthy groups were higher than healthy control groups (p ≤ 0.001). Nesfatin-1 levels of all DM groups were lower than all healthy groups, and nesfatin-1 levels of all CA-administered healthy and DM groups were lower than healthy and DM sham and control groups, but these were not significant (p > 0.001).
Conclusion: Although not significant, the decrease in nesfatin-1 level is evidence that CA has an anti-obesity effect in both healthy and diabetic rats. In contrast to its antihyperlipidemic effect in diabetic conditions, CA has hyperlipidemic effect in healthy conditions.
